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Gemcitabineor cancer stem cells have been the subject of great interest in recent years. In this
review we will use pancreatic cancer as an overall theme to draw parallels with historical ﬁndings to
compare to recent reports of stem-like characteristics in pancreatic cancer. We will cover such topics as label-
retaining cells (side-population), ABC transporter pumps, telomerase, quiescence, cell surface stem cell
markers, and epithelial–mesenchymal transitions. Finally we will integrate the available ﬁndings into a
pancreatic stem cell model that also includes metastatic disease.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
It is common to see poor drug responses or resistance after
repeated treatments of non-targeted chemotherapy in patients with
advanced malignancies, but the underlying causes are still not well
understood. One rationale for studying cancer-initiating or cancer
stem cells is to potentially determine if there is a rare subset of cells
responsible for this drug resistance problem and to unravel the
molecular mechanisms that govern their existence [1,2]. This review
will provide a critical analysis of current research in pancreatic cancer
related to cancer stem cells with a model that may provide a clearer
understanding of the process of tumorigenesis and progression using
pancreatic ductal adenocarcinoma (PDAC) as an example. A historical
background will set the stage for comparing and contrasting recent
reports and hopefully offer a better perspective of the cancer stem cell
ﬁeld in the context of PDAC.
2. Historical background
2.1. Origin of cancer stem cells
The theory of neoplastic disease, originating from developmentally
undifferentiated stem cells, was ﬁrst proposed by the cytological work+1 214 648 8694.
. Shay).
ll rights reserved.of pathologist Julius Cohnheim in 1867 [3]. His interpretation of
karyotypic chromosomal differences between epithelial and
mesenchymal tumors contributed to the characterization and under-
standing of tumor metastasis, which led to the belief that neoplasia,
was a ‘stem cell disorder’. During this era, one of the more prominent
proposals came from Boveri's hypothesis: ‘oncogeny by chromosomal
mutation’ [4]. The idea favored chromosomal number normalization
and tumor evolution through accumulation of precise mutations and
selective growth. Boveri's hypothesis led to the reemergence of the
‘stem-line concept’ as proposed by O. Winge in 1930 [5]. Koch's [6]
postulate states that primary tumors are heterogeneous and can be
enriched for highly metastatic sublines through in vivo selection, as
demonstrated using peritoneal injections of Flexner Joblin rat
carcinoma cells that led to highly metastatic ascites tumors. This
metastasis model did not reﬂect the entire process from initiation of
tumorigenesis to malignancy, and hence was not widely accepted
upon its publication [7]. In the early 1950s Klein and coworkers
developed a new model based on serial transplantation in vivo that
could give rise to primary tumors andmetastasis [8–12]. These studies
were the ﬁrst observations of the heterogeneous nature of tumor cell
populations, which suggested stem-like plasticity andmultipotency in
relation to neoplasia. The establishment of several ‘tumor stem-lines’
allowed researchers to address Boveri's hypothesis andWinge's ‘stem-
line concept’. The ‘stem-line’ concept postulated that tumors originate
from a normal stem cell where karyotypic changes determined the
stages of malignancy. This concept was revisited through
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Hauschka [13] and Foulds [14]], who used ascites tumors (developed
by Klein and Klein) to show that nonmalignant stem cells (NSC)
initially contained karyotypic constancy and normality, but subse-
quently underwent chromosomal alterations caused by environmen-
tal factors (i.e., carcinogens, radiation, and toxic compounds) [15] to
produce a main stem line (termed S) which was driven by
‘endomitotic reduplication’ of chromosomes [16–19] (Fig. 1). This
stage was then followed by progression into a secondary stem line S1,
which was deemed competent for transition to several cell fates
synonymous to stem cell differentiation [20,21]. Further environ-
mental selective pressures then cause chromosomal re-selection and
progression through ‘ascendant’ mechanisms to an invasive state
(termed M) resulting in malignancy [22]. The M state maintains
plasticity for metastasis or transition to a drug resistant line (DR) after
accumulation of speciﬁcmutations. The S stem line could also produce
a radiation resistant line (RR) by acquiring chromosomal changes
caused by severe DNA damage and exhibiting selective growth
advantage. Finally, a variant of the S stem line, a 2S polyploid line,
retained plasticity for alternative tumor progression that allowed for
further evolution of tumors [23] (Fig. 1).
2.2. ‘Minimal deviation’
Karyotypic characterization of the tumor stem-line concept,
using transplantable tumor lines in metastatic ascites tumors,
allowed phenotypic identiﬁcation of changes in the early stages of
malignancy. Dunning and Novikoff developed a series of hepatoma
cell lines, by providing carcinogens in the food to rats [24–26].
These cells displayed a less transformed phenotype based on
karyotypic characterizations. This led to the development of a rat
hepatoma line [27], termed ‘Morris hepatoma No. 5123’ [28], that
was similar to normal regenerative liver cells [29–35]. The No. 5123
transplantable hepatoma cell line had a slow growth rate and low
metabolic activity nearly identical to normal liver cells. The
heterogeneity of this population indicated both self-renewing
(undifferentiated) and differentiated cells similar to normal stem
cell phenotypes which led to the term ‘minimum deviation’ to
signify an early stage of tumorigenesis and malignancy [36] as
stated by the Boveri's hypothesis: oncogeny by chromosomal
mutation. These ﬁndings suggested that tumors arising from aFig. 1. The Hauschka model of tumor progression through stem lines. Adapted from
Hauschka in 1961 [13]. N = normal cell, S = main stem-line, S1 = secondary stem line,
M = malignant stem cell, DR = multidrug resistant stem cell with upregulated ABC
transporter pumps, RR= radiation resistant stem cell, 2S = polyploid stem cell variant,
DD = drug-dependent mutant, A = antigenic mutant; and L = mutations lethal for
individual tumor cells. A detailed discussion of this model is described in the original
publication [13].common progenitor can give rise to primary tumors that can further
progress to malignancy with ‘minimum deviation’ from the parental
stem cell of origin, creating a model to study early stage malignancy
and cancer stem cell differentiation.
2.3. Clonal evolution of a tumor
Although prior studies demonstrated tumor heterogeneity, it did
not address a ‘rare’ but highly malignant cell within a tumor or
whether the cell evolved by in vivo selection caused by microenviron-
mental differences. In 1967, Nowell's hypothesis, suggested clonality
and stem-line variation within a tumor, either by mitotic errors or
environmental selective pressure during malignancy, alluding to a
common ‘unicellular origin’ [37]. Fidler employed a model of lung
tumorigenesis and metastasis using a B16 melanoma cell line to
address Nowell's hypothesis and demonstrated that engraftment was
a rare event occurring in about one in a thousand events [38]. This
result suggested that tumor formation and metastasis was not only a
rare but perhaps, also a random (chance) event. Further experiments,
demonstrated that primary cells injected into mice maintained a
constant increase of nodules in the lungs that progressively became
more malignant compared to the original parental cell line after
successful rounds of in vivo selection. From this it was determined that
highly metastatic cells did not occur by random stochastic events
rather; they reﬂected a coordinated selective process for invasiveness,
lymphocytic recruitment, rapid growth advantage, and increased
angiogenic mediators [39–41]. Fidler also set up a series of experi-
ments designed to determine whether the heterogeneity of the
primary tumor cell line was due to the preexisting nature of
tumorigenesis or whether the cells re-established themselves accord-
ing to the tumor microenvironment to confer metastatic potential.
Fidler postulated that heterogeneity due to the origin of the tumor
should give varied tumor incidence, however if heterogeneity occurs
due to exogenous inﬂuences then the tumor incidence should be equal
to that of the line of origin. He selected cells based on colony formation
in soft agar and then injected them into mice to compare to the
parental cell line after several cycles (Fig. 2). These experiments
showed that a non-isogenic cell line gave rise to clones with varying
degrees of tumorigenicity and metastasis. This validated the idea of
metastasis being a coordinated and selective event rather than a
random stochastic event [42,43]. These ﬁndings were consistent with
Nowell's hypothesis of heterogeneous tumor stem-lines giving rise to
a varied population of sublines by preexisting mechanisms possibly
due tomitotic errors or accumulation of precise mutations to the stem
cell of origin.
2.4. Label retaining cells
Stem cell stability, balance of stem cell pools and protection from
somatic mutations are some of the reasons that cells may evolve
mechanisms for protection from standard chemotherapeutic agents.
As such, at least two plausible hypotheses have been proposed; stem
cells maintain pools within tissues as required during turnover or
tissue damage, and stem cells retain their parental DNA strand during
asymmetric division (differentiation) to increase lifespan and protect
against DNA replication error prone mutations, historically referred to
as the Cairns' hypothesis [44].
Almost universally, non-targeted chemotherapeutic drugs affect
cancer cells based on proliferation compared to normal generally
slowly or non-dividing cells. However, if a subset of cancer cells are
held in a state of ‘quiescence’ (G0) either by stimulus deprivation or
inhibition of cell cycle entry it could potentially diminish drug
responses and may eventually permit tumor recurrence after the
therapy regimen ends. This does not include resistance, as ‘resistance’
is deﬁned as the genetic tolerance of chemotherapeutics in proliferat-
ing cells. A ‘rare’ slow cycling stem cell that stalls in G0 or rarely enters
Fig. 2. The Fidler method of metastatic clone isolation. Adapted from Fidler [42,43]. Tumor cells from a non-isogenic B16 melanoma line are grown in soft agar and clones are picked
for mouse injections. After 18 days, lung metastases are isolated and the procedure is repeated to enrich for a highly metastatic cell population. This method was used to determine
whether the heterogeneity of the primary tumor cell line was due to the preexisting metastatic cells or whether the cells re-established metastatic cells based on the tumor
microenvironment. These studies showed that metastasis was a coordinated and selective event rather than a random stochastic event.
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with tritiated thymidine (H3-thymidine or 3HTdR) [45]. This is
referred to as the ‘label-retaining cell’ (LRC) as has been reported in
one case of cancer stem cells [46]. It has been shown that cellular
dormant cancer cells are G0–G1 arrested and therefore may explain
the occurrence of label retention at the earliest point of tumorigen-
esis. Tumor dormancy occurs when a primary tumor or dissemi-
nated tumor cell has entered G0 and has delayed its ability to exit or
reenter the cell cycle. After drug treatment the bulk tumor is often
reduced, but a dormant population may survive and exist as minimal
residual disease that can reemerge years later by mechanisms that
are not well understood. Metastatic events may occur due to
activation of dormant disseminated tumors cells at distal organs, and
it is this event that may increase the morbidity and mortality
associated with advanced malignancies. There are three cellular
mechanisms of tumor dormancy: immunosurveillance, angiogenic
switching, and cellular dormancy [reviewed by Aguirre-Ghiso [47]].
Cellular dormancy may be the most relevant as this is where
primary or disseminated tumor cells are dependent on their
microenvironment and held at G0–G1 arrest. An unknown biochem-
ical change in the local environment releases these populations from
arrest. The observation of label-retaining cells within a tumor may
be explained by cellular dormancy, and its asymmetric transition to
transit ampliﬁcation may depend on the biochemical change in the
tumor stem cell niche, yet to be deﬁned, similar to normal stem cells
[48,49]. An understanding of the G0 dormant state of label-retaining
cells may allow characterization of why tumor cells evade therapy
and potentially provide insights on how to induce dormant cancer
cells out of the G0 state and make them vulnerable to conventional
anti-proliferative therapeutic agents.
2.5. The ‘side population’
The demand for therapeutic regenerative medicine fueled the
discovery of the ‘side population’ (SP), which was initially used to
identify the pluripotent hematopoietic stem cell compartment within
the bone marrow [50]. These cells have the potential to repopulatetheir own ‘self-renewing’ pool and manage hematopoietic stores, or
differentiate into lineage speciﬁc lymphoid and myeloid cells to
replenish the turnover of cells within the immune system. One idea
was that these isolated ‘side population’ stem-like cells evolved
mechanisms to avoid natural xenobiotic toxicity by expressing ATP-
dependent cell surface pumps referred to as ABC (ATP binding
cassette) transporters [51,52]. Since the expression and activity of ABC
transporters are elevated in normal stem cells this led to testing if
these pumps were able to efﬂux lipophilic ﬂuorescent DNA inter-
calating dyes. Thus cells that were able to efﬂux dyes have been
termed the ‘side population’ cells, since they are identiﬁed in the
ﬂuorescence activated cell sorter as cells that do not retain dye (Figs. 3
and 5). Similarly to normal cells, in almost all primary human cancers
there are a subset of cells that have either upregulated their
transporters or retained the expression of the transporters from the
cell of origin based on their ability to efﬂux dyes. This provided
additional evidence that a subset of cancer cells may be similar to side
population normal stem cells and these rare cancer cells may be
important in the sustained growth of cancer as well as evasion from
chemotherapeutic agents. Analysis of SP cells from acute myelogenous
leukemia cells (AML) co-labeled with cells carrying normal HSC
markers was reported to correlate with poor patient outcome [53,54].
In the case of chemoresistance, it was shown that several cancers
accumulate mutations or genetic changes to increase pump activity,
predominantly theMDR-1 transporter and to a lesser degree theMDR-
3 pump [52]. Chemotherapeutic drugs such as paclitaxel and
vincristine are substrates for these transporters, shedding light on at
least one of the underlying mechanisms that may be important in
relapse or poor initial drug responses. ABC transporters have become a
target for therapeutic development in cancer. In one case, verapamil a
calcium channel blocker normally used for hypertension was used to
inhibit ABC pumps active on cancer cells, rendering them vulnerable
to mitoxantrone (a toposiomerase II inhibitor) toxicity [1]. These
ﬁndings support the concept that a subset of a heterogeneous
population of cancer cells initially contain or have the capacity to
acquire a conserved molecular mechanism of survival against
xenobiotics or chemotherapeutics agents by expressing dye efﬂuxing
Fig. 3. Selection process to establish Panc-1 subclones. (A) Panc-1 cells are plated by limiting dilution into a 96-well plate and cultured for two weeks at which time clones were selected based on a ductal or transformed phenotype.
Characterization of Panc-1 subclones. Panc-1 clones (B) B10 tumorigenic (ductal), (C) C4 tumorigenic/mildly metastatic (ductal), (D) C5 tumorigenic/highly metastatic (transformed), and (E) F9 tumorigenic/highly metastatic (transformed)
were analyzed by FACS for their SP content.
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marker “SP” is sufﬁcient to be classiﬁed as a cancer stem cell.
2.6. Cancer stem cells and tumor initiators
The observation that a rare cell within tumors can initiate a
malignant phenotype is due to a conserved primordial cellular
mechanism equivalent to its normal stem cell counterpart is a
rediscovered paradigm shift in the cancer ﬁeld. The concept is that
self-renewal is the maintenance of a rare cancer stem cell and the
more committed or differentiated cells make up the bulk of a tumor. It
is becoming widely believed that the molecular and cellular
characterization of these cells may be critical in understanding
tumorigenicity and metastatic disease and the elusive nature of
cancer stem cells.
The ﬁrst identiﬁcation of CSCs was demonstrated by reconstitution
of AML in immunodeﬁcient mice using cells isolated based on CD34+/
CD38− markers from acute myeloid leukemia (AML) patients. The
engraftment demonstrated self-renewal by expansion of CD34+/
CD38− and differentiation by asymmetric division to blast cells,
eosinophils, and basophils and was referred to as the ‘tumor-initiating
cell’. Ensuing reports showed that these puriﬁed populations of
tumor-initiating cells were pluripotent and could establish a hetero-
genic hierarchy after engraftment, implying that transformation to
leukemia occurs in a more primordial hematopoietic stem cell rather
than a more committed or differentiated cell [55]. The next successful
demonstration of cancer stem cellswas in brain tumorswhere CD133+
(Prominin 1) expressing cells, referred to as brain tumor stem cells
(BTSC), were isolated from patients and assayed in vitro for self-
renewal and differentiation. The established method of culture and
spheroid formation allowed the identiﬁcation of self-renewal by
expansion of the CD133+ cells and differentiation by asymmetric
division to astrocytes, neurons, and oligodendrocytes [56]. Both of
these results determined that cells isolated based on speciﬁc cell
surface markers were able to retain their plasticity from the stem cell
of origin. In addition, the rare cells could initiate xenograft tumors
with considerably fewer cells compared to cells without the cancer
stem cell “markers”. These ﬁndings appear to validate ‘Boveri's
hypothesis: oncogeny by chromosomal mutation’ and the concept of
‘minimal deviation’ where genetically altering mutations in brain
tumors or genetic fusions (Bcr-Abl) in leukemic cells occur earlier in
the stem cells lineage thereby retaining their plasticity, as proposed by
Morris and Potter in the 1960's. A connection between dye efﬂuxing
‘SP’ cells and these cell surface markers have not been clariﬁed.
2.7. Pancreatic stem cells
There are three major mediators of pancreatic development that
determine cell fate of the progenitors from the foregut endoderm. The
initial commitment of the endoderm to the premature pancreatic bud
involves the loss of sonic hedgehog pathway activation and an
increase expression of the homeobox gene PDX-1 [57]. Final establish-
ment of a complete organ involves stem cell fates to four major cell
types by loss of notch signaling. Each unique cell type increases
expression of a protein, which correlates with its differentiation from
the stem cell of origin or lineage speciﬁcity. Each cell type carries a
different marker, for example, the islet cells produce insulin, acinar
cells express amylase, ductal cells express DBA (Dolichos Biﬂorus
Agglutinin), and centroacinar cells express HES1 (Hairy and Enhancer
of Split I) an indication of stem cell phenotype [58–67]. Although the
pancreas has limited regenerative capacity, and there has been no
report of primordial cells present, it has been suggested that
centroacinar cells are the precursors to acinar and ductal cells [57],
and may act as a transition cell prior to complete differentiation. Due
to their self-renewal and differentiation capacity, they may be the
target cells of origin for PDAC.3. Pancreatic cancer stem cells
The idea that a stem-like cancer cell may be the cause of
chemoresistance and relapse in patients with pancreatic cancer
carries considerable impact in the development of speciﬁc and more
effective therapeutics. Several reports have made considerable
contributions to the understanding of pancreatic cancer and most
have alluded to stem-like characteristics either in vitro or in vivo.
Cancer stem cells have taken front stage in attempting to understand
the mechanism behind the elusive character of a cancer cell and
signiﬁcant efforts have been made to identify these ‘rare’ cells, from
primary solid tumor tissues of patients with pancreatic cancer as well
as from pancreatic tumor cell lines.
3.1. Patient samples
Isolation of a putative pancreatic cancer stem cell was ﬁrst
reported utilizing a series of cell surface markers from human PDAC
tissues samples that had tumor-initiating properties in immunodeﬁ-
cient mice [68]. The guidelines used were previously established by
identifying CD44+/CD24low/ESA+ breast cancer cells as having
tumor-initiating characteristics in mice. However, pancreatic tumor
initiators were shown to have a slightly different marker proﬁle.
Subcutaneous xenograft injections in the ﬂank produced tumors at a
density of 100 CD44+/CD24+/ESA+ cells per injection that pheno-
typically resembled the human tumor of origin. Several combinations
of these markers were tested to verify the maximum tumor-initiating
capacity amongst these populations. The researchers also utilized two
other models, a peritoneal injection model where cells were injected
into the abdomen of the animal, and an orthotopic model where cells
were directly injected into the tail portion of the pancreas. The
peritoneal model resulted in tumor initiation of CD44+/CD24+/ESA+
cells at a frequency of 500 cells injected, and the orthotopic model
initiated tumors at a frequency of 5000 cells injected as compared to
CD44−/CD24−/ESA− cells (which did not produce tumors when 5000
cells were introduced). The central question is if this is sufﬁcient
evidence for the pancreatic stem cell hypothesis of cancer. Based on
Nowell's hypothesis and Fidler's work, these variations are justiﬁed by
clonal selection and not necessarily by their rarity or stemness. In
normal stemcells, theremaybedifferences in the rate of cellulardivision
between parental cells and their progeny. However, cell cycle analysis of
these distinct populations did not differ in rates of proliferation (e.g. not
quiescent) indicating that the so-called ‘progeny’ have not truly
differentiated from the tumor-initiating parental cell, but may have
altered their cell surface marker proﬁle based on extracellular cues.
What remains a mystery is if the cell cycle has not changed between
each population, then how can they differ in tumor initiation?
In an attempt to demonstrate that these isolated populations
retained their plasticity, peritoneal tumor tissue was stained with
differentiation markers such as S100P and stratiﬁn. If the CSCs had
retained their ability to differentiate, then the stained peritoneal
tumors should have indicated a hierarchy as seen in previous CSC
reports. This was not robustly supported in the data presented. The
staining appeared to be a preexisting expression of differentiation
markers, as compared to the tissue of origin, and may not have been
mechanistically related to the loss of CD44/CD24/ESA. Therefore the
heterogeneity may be due to the clonal evolution of the tumor as
suggested by Fidler and Nowell and not necessarily due to the stem
cell of origin. The purpose of these experiments, in general, is to justify
the ability of single cells to have the plasticity to initiate a tumor and
differentiate into distinct progeny contributing to an observable
tumor hierarchy. Based on the data reported, there seems to be no
hierarchy, just a correlation of reconstitution.
Finally, quantitative PCR of the developmental signaling molecule,
sonic hedgehog (SHH) was shown to be ampliﬁed nearly 50-fold in
the highly tumorigenic population. What was not shown is whether
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hedgehog is a soluble extracellular ligand of PTC and therefore
dependent on the cells of the tumor microenvironment for secretion.
An ideal demonstration of stem cell pathway regulation would have
been to quantify PTC/Smo target gene Gli to show bona ﬁde activation.
The increase in SHH message can be interpreted as an indication of an
autocrine loop, however without Gli expression data one cannot
determine whether the pathway is active. While the authors of this
article [68] made an attempt to identify a putative pancreatic cancer
stem cell, the data presented when examined carefully can have
multiple interpretations and not all are consistent with the current
views of a cancer stem cell.
3.2. Cell lines
There are three reports of stem-like characteristics within
established pancreatic cancer cell lines. The ﬁrst report uses historical
markers, ABCG2+ from leukemia and CD133+ from glioblastoma, to
screen a select panel of cells lines for stem-like characteristics [69]. In
particular, ABCG2 correlates with the ‘side population’ phenotype in
cells isolated from the bone marrow (reviewed in introduction). In
this report, it was shown by relative RNA expression that all ﬁve
pancreatic cancer cell lines contained ABCG2 mRNA. Surface immu-
nostaining of ABCG2 and analysis by FACS resulted in 2–7% positive
staining of the total population from each cell line. Actually, detailed
analysis of the secondary ‘only’ IgG2b, as well as the negative control
cell line SaOS2 FACS proﬁles indicated a signiﬁcant background that
may have contributed to the positive ABCG2 staining. Thus the 2–7%
positive staining result is only slightly above background and possibly
insigniﬁcant. The authors of this work concluded that none of the
pancreatic cancer cell lines contained an SP phenotype by FACSFig. 4. Colony formation assay of stem-like fractions in Panc-1 cells. The independent growth
100 and 300 in triplicate directly from an SP FACS sort and cultured for 14 days, colony couanalysis. However this is contrary to our own observations (Fig. 5A) as
well as those reported by Zhou et al. [70]. Despite failing to detect SP,
the report makes the correlation that if a control cell line such as MCF-
7 cells contains an SP phenotype with detectable ABCG2 expression
then the detection of ABCG2 in pancreatic cancer cells implies an SP
phenotype. It is possible that not all ﬂuorescence activated cell sorters
can detect the SP phenotype, therefore these ﬁndings would have to
be conﬁrmed by using a more sensitive instrument before drawing a
negative conclusion of these cell lines. Following this, expression of
CD133+mRNAwas shown to be moderate in two pancreatic cell lines,
PancTu1 and A818-6, of which 2% of the total population stained
CD133+ positive by FACS analysis as compared to the positive control
cell line SaOS2. This may be signiﬁcant, as CD133+ has been used for
the isolation of brain and colon cancer stem cells. However, further in
vivo experiments would have to be conducted to determine any
biological signiﬁcance.
The second report uses spheroid formation to demonstrate stem-
like characteristics in vitro [71]. The Panc-1 cell line was used to
establish spheroids with serum (SCM) and serum-free medium with
supplements commonly used to culture stem cells (SFM). The data
indicated that a single cell could generate an adherent spherical
cluster that was capable of being continuously propagated in SFM.
Although common practice is to show spheroid formation of a three
dimensional (3D) non-adherent free ﬂoating body, synonymous to
embryoid bodies from ES cells, it may be that these two dimensional
(2D) structures are representative of clusters rather than spheroids.
Since the SP phenotype correlates with stem cells, the clusters were
treated with Hoechst 33342 dye to test their dye efﬂux capacity by
ABC transporters. Panc-1 cells grown in SCM contained clusters that
were heterogeneous for dye efﬂux while cells grown in SFM gave rise
to colonies that varied in their ability to efﬂux dye and responses topotential of a single cell from the SP, MP, and TP fractions were tested (A–C), by plating
nts of SP, MP, and TP fraction at 100 and 300 cells plated per plate (D).
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data is consistent with our own ﬁndings where cells were plated at
clonal density (Fig. 3A) and clones were isolated for SP analysis (Fig.
3B–E). Indeed the Panc-1 cell line is heterogeneous for the SP
phenotype. In support of this, a reverse cloning experiment, where
isolated SP (side population), MP (main population), TP (total
population) cells were plated at clonal density showed no clear
difference in clonal efﬁciency (Fig. 4). This indicates that each
population has similar cloning efﬁciencies but lacks phenotypic clonal
heterogeneity within each puriﬁed population (SP, MP, TP). The dye
efﬂux activity in these clusters indicates a conserved trait from the
stem cell of origin and can be referred to as ‘minimally deviated’ as
suggested by Nowell and Potter [28,36,72]. Since there is no
phenotypically distinct progeny observed in these clusters, variation
in degrees of dye efﬂux between colonies may be due to the clonal
evolution of the tumor similar to the ﬁndings of Nowell and Fidler
[37,42] and not necessarily stem-like mechanisms. Additionally, the
difference in tumorigenicity was tested between cells grown in serum
free and serum containing medium by intraperitoneal injections into
nude mice. The serum free grown cells were more tumorigenic,
however, this may not be due to the stemness of these cells, but
caused by the mitogenic culture conditions containing bFGF and EGF.
The third report uses appropriate instrumentation to identify a
bona ﬁde SP phenotype in the Panc-1 cell line [70]. The population
was shown to have ∼10% SP that was completely abrogated by
verapamil inhibition as well as an observable dye efﬂux capacity in 2DFig. 5. Enrichment of SP by serial sub-culture in vitro. The ‘side population’ assay. Live cells a
from the dye are plotted on a log scale. The ‘R1’ gate designates the ‘side population’ (SP). (
dishes, (B) cultured for one week and reanalyzed, resulting in an increase of the SP fraction
fractions, (C) resulting in 10% SP. MP cells from this sort were plated onto dishes. (D) S
identiﬁcation of 5% SP either by residual or by conversion.culture by microscopy. However the authors did not report any
biological function (e.g. increased tumorigenicity) as shown in other
cell types such as enrichment of the SP phenotype by serial passage
nor did they attempt to identify whether the SP and MP were
exclusively pure of each other as shown in our own observations
(Fig. 5). Real-time gene expression analysis of ABCB1 and ABCG2
mRNA demonstrated a possible 4-fold difference in pump activity
between SP and main population (MP) or non-SP cells. Historically,
ABC transporters are thought to be evolutionarily conserved pumps
for the protection of stem cells against xenobiotics [51]. In most cases
they are upregulated in cancers to efﬂux vinca alkaloid and taxane
drugs as a form of resistance. In this article [70] the authors report that
the presence of SP confers resistance to gemcitabine, a commonly
used chemotherapeutic drug for treatment of PDAC. Treatment of cells
with gemcitabine increased the SP fraction 3-fold indicating that the
non-SP fraction was being targeted by gemcitabine. This is consistent
with previous reports indicating that a slower cycling SP cell would be
more resistant to a nucleoside analog [73]. If gemcitabine were acting
as a substrate then this would be the ﬁrst report of a nucleoside analog
being pumped by an ABC transporter so further investigation of these
ﬁndings are needed.
These three reports have considerable descriptive evidence of
stem-like behaviors in the Panc-1 pancreatic cancer cell line. Themost
common feature is the ability to efﬂux Hoechst 33342 dye by ABC
transporters, which implicates ABCG2, reported in hematopoietic
stem cells, and ABCB1, upregulated in several cancers, as the exactre stained with Hoechst 33342 dye, gated for live cells, and dual emission wavelengths
A) SP fraction from Panc-1 cells make up 10% of the total population, were sorted onto
to 50%. Identiﬁcation of SP within isolated MP. Panc-1 cells were sorted for SP and MP
P analysis of MP the plated MP fraction after sub-culture for four weeks resulted in
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report previous observations of an ABC transporter that is highly
expressed in the Panc-1 cell line, ABCC1 or MRP-1, which may be the
pump that drives the SP phenotype. The reports demonstrate that a
verapamil sensitive pump confers resistance to vinca alkaloids and in
rhodamine 123 accumulation assays [74–76]. Western blot analysis
showed that ABCB1/P-gp is not present at all, but MRP-1 is present. It
is for this reason that qPCR analysis of ABC transporters may require
copy number quantiﬁcation rather than relative expression. Further
experiments by knockdown of these transporters are required to
deﬁnitively implicate their activity as related to the SP phenotype.
3.3. Metastasis
It is important to not only identify markers of cancer stem cells but
also if or how cancer stem cells become metastatic. In an attempt to
isolate pancreatic CSCs, Hermann et al. [77], discovered a rare subset of
highly tumorigenic and metastatic cells located in the invasive border
zone of pancreatic cancer tissues. Using a CSC marker identiﬁed in
glioblastoma CSCs, CD133+, and CXCR4, a marker of cell migration, a
panel of human PDAC tissue samples was stained for co-localization. A
rare subset of double positive cellswas localized to the invasive front of
the tumor. Tumor initiation and serial transplantation experiments
using CD133+ and CD133− cells isolated from patient samples
indicated that CD133+ cells initiated tumors using an inoculation of
500 cells while CD133− did not give rise to tumors. Unlike brain CSCs,
where CD133+ spheroids can be differentiated into multi-lineage
progeny, CD133+ pancreatic cancer cells grown in spheroids become
enlarged upon exposure to differentiation conditions, but they show
no clear morphological change to a different cell type. Further
experiments using two cells lines that were selected for high and
low degrees ofmetastasis were sorted based on CD133 and CXCR4. The
results indicated that both cell lines contained CD133+ cells and could
initiate tumors, but only CD133+/CXCR4+ double positive cells within
the metastatic cell line could give rise to tumors that disseminated in
the blood stream. This correlated well with metastasis found in
patients. Interestingly, when these tumors were stained for the
epithelial cell marker, cytokeratin, the CD133+ cells were negative
but the CD133− cells stained positive. Coincidentally the loss of
cytokeratin may be an indication of epithelial to mesenchymal
transition (EMT), which is a hallmark of metastasis. Recently a report
demonstrated thatwhen highly tumorigenic cancer cells undergo EMT
they begin to express tumor-initiator markers [78]. It is possible that
these CD133+ cells have undergone EMT and may explain their tumor
initiating and highly metastatic phenotype. Finally, one of the
purposes of studying CSCs is their resistance to standard chemother-
apy. Cell cycle analysis revealed CD133+ cells were slower dividing
than CD133− cells, indicating an effect that confers resistance against a
nucleoside analog drug such as gemcitabine.
Finally, a PTEN knockout in the mouse pancreas served as a model
of pancreatic ductal adenocarcinoma (PDAC). The investigators
observed an expansion of centroacinar cells, increased expression of
HES1, and decreased expression of amylase from the surrounding
tissue. The expansion of centroacinar cells eventually progressed to
PDAC [57]. These ﬁndings support the idea that centroacinar cells are
the source of stem cells of the acinar and ductal cells and perhaps the
precursor cells that are transformed prior to PDAC. However, other cell
surface markers or dye efﬂuxing capability was not reported.
3.4. Telomerase therapy in cancer stem cells
Pancreatic adenocarcinoma often presents in its late stages and is
almost universally unresponsive to many conventional therapies [79].
In many cases, after attempts to treat the disease, the tumor becomes
chemoresistant resulting in the poor prognosis of most pancreatic
cancer patients. There have been many studies characterizing thecause of this resistance. One common reason is the upregulation of
ABC transporter pumps that rapidly eject vinca alkaloids or taxanes
from the cell. The ﬁndings that pancreatic cancers becomes resistant
to gemcitabine is quite rare, but in the case of nucleoside analogs,
which are not substrates for ABC transporters, the cause of resistance
may be an increase in Bcl-XL expression that can allow incorporation
of normal nucleosides but not toxic analogs [80]. The central question
is if a small ‘rare’ subset of stem-like cancer cells retains their
transporter activity or anti-apoptotic genes that will eventually
dominate the content of the tumor.
There are several reasons why tumors recur, such as poor delivery
of chemotherapeutics or rapid efﬂux of vinca alkaloids and taxanes via
ABC transporters. The use of gemcitabine has become the primary
treatment for pancreatic cancer when surgical resection is not
indicated, however the response has been at best modest [81].
Gemcitabine is a nucleoside analog that is incorporated into DNA in
substitution of cytidine, therefore, inducing apoptosis by genomic
instability [82]. This drug is more effective than classical drugs
because it is not a substrate for ABC transporters, its resistance is rare,
which would imply that the cause of recurrence is either due to poor
drug delivery or that a quiescent stem-like cell is able to evade
treatment.
Telomerase (hTERT), a cellular reverse transcriptase, has been
shown to be active in greater than 90% of all tumors [83] and has a cell
cycle component to its expression [84]. The telomerase holoenzyme is
made up of two core components necessary to synthesize telomeric
DNA (TTAGGG) to the end of chromosomes, the catalytic protein
subunit (hTERT) and the functional or template RNA (hTR or hTERC).
Most stem cells have moderate to low telomerase activity and are
generally quiescent [85]. It has been shown that telomeres become
progressively shorter over time in normal cells that divide (these cells
generally are telomerase silent or low expressing). When telomerase
is repressed in proliferating cancer cells the cells die and in vivo the
tumors regress [86]. The idea that telomerase contributes to the
immortality of cancer cells is well established, but it is not as well
known if the CSCs also express telomerase activity or if cancer stem
cells become quiescent similarly to normal stem cells. If cancer stem
cells are quiescent, then telomerase should not be highly expressed.
Telomerase has been implicated in most solid tumors of epithelial
origin. Several attempts to use standard reverse transcriptase
inhibitors have shown they are too toxic to the host using doses
required for telomerase inhibition for clinical applications [87–89].
Recent advancements in oligonucleotide chemistry have allowed the
design of a competitive telomerase template antagonist (13-mer thio-
phosphoamidate backbone conjugated to a palmitoyl (C16)). This
compound, GRN163L, has a longer cellular half-life at 37 °C and
increased potency against their targets over other oligonucleotide
backbones and has minimal toxicity to the host [86]. The use of thio-
phosphoamidate backbones in oligonucleotides as well as lipidation
has proven to be well tolerated in pre-clinical applications [90–93].
The recent development of a telomerase inhibitor using this
technology has prompted its application to many cancers in early
stage clinical trials [94]. In this case the telomerase oligonucleotide
(GRN163L) was not used as an antisense inhibitor to hTERTmessenger
RNA, but targeted to bind the template region of the functional RNA
(hTERC). Thus the GRN163L telomerase inhibitor acts as a competitive
telomerase template inhibitor. Panc-1 cells sorted by the SP assay
demonstrate robust telomerase activity that is inhibited when treated
with GRN163L (Fig. 6). The SP fraction had slightly less telomerase
activity as shown by the complete retention of internal telomerase
activity standard (ITAS) compared to the MP (main population). The
reduced activity in the SP population could be explained if the SP are
initially cycling slower than the MP compartment. Irrespective, both
fractions (SP and MP) expressed robust telomerase activity and were
sensitive to the GRN163L treatment as shown by almost complete
inhibition of the TRAP ladder. This demonstrates that pancreatic
Fig. 6. Telomerase activity in cancer stem cells and inhibition using GRN163L. Panc-1
cells were sorted by SP-FACS onto a 6-well culture dish and cultured for three days in
the presence or absence of GRN163L drug and assayed for telomerase activity.
256 V.J. Bhagwandin, J.W. Shay / Biochimica et Biophysica Acta 1792 (2009) 248–259cancer SP cells are not completely quiescent. Thus, a major difference
between normal and cancer stem cells may be that cancer stem cells
cannot become completely quiescent.
Telomerase inhibition is a novel and almost universal tumor target
and has been the subject of numerous preclinical studies and recently
clinical studies. Since SP cells may not be quiescent but cycle slower
than MP cells, this may help explain why SP cells tolerate gemcitabine
treatment. The response to GRN163L shows that the mode of action is
independent of the rate of cell cycle and validates the use of
competitive inhibitors to telomerase for targeting pancreatic putative
cancer stem cells. The anti-proliferative effects of gemcitabine have
been well characterized and approved for use against pancreaticFig. 7. Pancreatic cancer stemmodel. A pancreatic adult stem cell, possibly centroacinar cells,
may have label retaining cell (LRC) properties. This cell can upon appropriate stimulation
asymmetrically divide giving rise to MP cells. The MP cells makeup the bulk of the tumor an
EMT and may clonally evolve the tumor to malignancy.cancer, but due to enhancement of anti-apoptotic genes the tumor
response is very low. The development of a competitive template
inhibitor of telomerase provides new approaches to anti-cancer
therapy. It may be that the increase of anti-apoptotic genes during
gemcitabine treatment are resolved by telomerase inhibition by
reduction of the expression of these genes due to ‘uncapping’ of the
telomeres (uncapped telomeres create a DNA damage signal), and
therefore suggests telomerase as a ‘hinge-pin’ for targeting bulk tumor
cells and perhaps cancer stem cells. In a practical sense, reducing the
bulk tumormasswith gemcitabine in combinationwith GRN163Lmay
provide for more durable responses.
Finally, the characterization of the development of the pancreas
has revealed two additional targetable stem cell regulatory pathways
for differentiation. The ﬁrst was the hedgehog pathway where loss of
hedgehog signaling led to pancreatic bud development [95–97].
Several reports show a reactivation or retention of hedgehog signaling
after transformation giving rise to tumors ‘trapped’ in the process of
self-renewal [98–100]. Second was the notch pathway where loss of
notch signaling gave rise to endocrine and exocrine cells [59–67].
Several reports show a reactivation or retention of notch signaling
after transformation to PDAC [101,102]. If these pathways are intact
and responsive, then targeting the mediators within these pathways
may be beneﬁcial and in combination with telomerase inhibitors may
provide new therapeutic approaches. One approach may be a
depletion model where self-renewal driven by an active notch
pathway is diminished using a small molecule inhibitor against γ-
secretase, the enzyme that generates the notch intracellular domain
(NICD) activator [103–105], or by using cyclopamine, a competitive
inhibitor of SHH binding to the PTC receptor in the hedgehog pathway
[106]. The combination of these inhibitors along with the telomerase
inhibitor, GRN163L may prove to be beneﬁcial.
4. Conclusion
This review attempted to draw parallels with historical ﬁndings as
compared to recent reports of stem-like characteristics in the
pancreatic cancer ﬁeld. The descriptions of chromosomal aberrationsundergoes mutagenic transformation and takes on a state of ‘minimal deviation’, which
can either self-renew/symmetrically divide similar to SP drug resistant cells or divide
d are non-metastatic, but with further transformation/secondary mutations can induce
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marked the earliest known characterization of the origin of cancer
stem cells. However, these observations laid dormant until Boveri's
hypothesis of oncogeny by chromosomal mutations [4] that was
further described by O. Winge's stem line concept [5]. This led to the
development of new animal models by Koch [6], Klein and Klein
[8–12] that allowed the discoveries of tumor heterogeneity and
detailed elucidation of the stem line concept by Makino, Levan and
Hauschka [13,16–21,23]. Further studies by Dunning and Novikoff led
to the understanding of the earliest neoplasia events termed ‘minimal
deviation’ to describe the earliest state of the transformed stem cell
[24,25,72]. Finally, the observations by Fidler and Nowell [37–43,107]
led to the understanding of the clonal evolution of a tumor from a
transformed stem cell. These historic ﬁndings implicate a primordial
adult stem cell as the origin of cancer and provide a solid rationale for
more contemporary investigations into the biological mechanisms
involved in chemoresistance and tumor relapse.
In cells obtained from pancreatic cancer patients, a deﬁned set of
markers have been reported by Li and coworkers [68] that can identify
a population of cells that are highly tumorigenic, can self-renew, and
differentiate synonymously to normal stem cells. However, these
studies did not take into account that what is being called ‘self-
renewal’ can also be interpreted as an expansion due to over-
expression of cyclin D1 and differentiation can be interpreted as an
oncogenic-induced expression of differentiation markers. Therefore,
these recent experiments mechanistically recapitulate work already
reported by Fidler and Nowell but with more detailed markers in
identifying tumor-initiators and not necessarily cancer stem cells.
Additionally, others have reported that pancreatic cancer cell lines
exhibit dye efﬂux capacity in vitro [69–71]. This could be a marker
reﬂecting the ‘minimal deviation’ retained from the stem cell of origin
as similarly shown by Morris [32–34], but these studies did not
demonstrate any signiﬁcant in vivo biological function and therefore
the reports remain anecdotal. Another group reported [77] that a
highly metastatic cell population expresses cancer stem cell/tumor
initiator markers that have lost their epithelial cell marker, cytoker-
atin, but retain some plasticity similar to stem cells. This report is
apparently based on recent reports that cells undergo EMT express
cancer stem cell/tumor initiator markers, are highly metastatic, and
lose their cytokeratin expression. Finally, a report demonstrated that
loss of PTEN speciﬁcally in the pancreas induced expansion of the
centroacinar cells that eventually progressed to malignancy and was
the ﬁrst evidence that a primordial adult stem cell may be the origin of
PDAC [57]. Taking these results along with some of the data presented
in this review, we have devised a model that may explain the cell of
origin and stem-like plasticity of these cells that gives rise to PDAC
(Fig. 7).
Pancreatic cancer has proven to be elusive to most chemother-
apeutic drugs. In the case of vinca alkaloids and taxanes the ABC
transporters are most likely responsible. In the case of nucleoside
analogs it may be the inherent slow dividing nature of subset of
cancer cells that make them resistant to these drugs. What is not
discussed in any of the reports above is the label retaining (LRC)
properties of putative cancer stem cells. LRC's are thought to be slow
growing perhaps quiescent cells and thus may be prime candidates
for targeting, as they are elusive to most antiproliferative drugs [46].
However, our studies show that telomerase activity (hTERT) is the
universal gatekeeper of immortality, and both drug resistant/slow-
dividing cells and non-resistant/rapid dividing cells express hTERT
and therefore validates telomerase activity inhibition as a universal
target for bulk tumor cells as well as putative cancer stem cells.
Being that telomerase inhibitors may be implicated in the uncapping
of telomeres and inducing a chronic DNA damage response, it is
plausible to assume that this targeting strategy may also evade
Bcl-XL anti-apoptotic events [80] and therefore have multiple
levels of effects.Based on historic ﬁndings and current reports one can evolve a
series of guidelines that may be robust for the isolation and study of
cancer stem cells as follows. First, markers should be identiﬁed to
isolate transformed cells that initiate a tumor and retain plasticity
synonymous to the primordial adult stem cell of origin (e.g. self-
renewal and differentiation) similar to reports of Dick and Dirks
[55,56]. Second, the isolated cells should have a ‘minimally deviated’
phenotype, in terms of karyotype and enzyme function as suggested
by Morris and originally proposed by Boveri and Winge. Third, the
puriﬁed population of cells should have expression of evolutionarily
conserved stem cell genes such as ABC transporters and telomerase.
Fourth, since tumors cells are not normal stem cells it is not clear if a
quiescent population as shown by label retention will be important
but it should be assessed. Fifth, these putative cancer stem cells should
have intact and responsive developmentally regulated signaling
pathways (e.g. sonic hedgehog, Wnt, Notch, TGF) that are potentially
targetable. Finally, this population should retain the ability to undergo
clonal evolution as suggested by Fidler and Nowell, and further
progress through EMT to malignancy. The compliance with of these
criteria will lead to an extensive knowledge of putative cancer stem
cells that will reveal signiﬁcant exploitable therapeutic targets.
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